The estrogen metabolites 2-methoxyestradiol and 2-hydroxyestradiol inhibit endometriotic cell proliferation in estrogen-receptor-independent manner

References

• Child TJ, Tan SL. Endometriosis: aetiology, pathogenesis and treatment. Drugs 2001;61:1735–50.
   PubMed Web of Science ®Google Scholar
• Giudice LC, Tazuke SI, Swiersz L. Status of current research on endometriosis. J Reprod Med 1998;43:252–62.
   PubMed Web of Science ®Google Scholar
• Smith S, Pfeifer SM, Collins JA. Diagnosis and management of female infertility. JAMA 2003;290:1767–70.
   PubMed Web of Science ®Google Scholar
• Bulun SE. Endometriosis. N Engl J Med 2009;360:268–79.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Cheng YH, Pavone ME, et al. 17Beta-hydroxysteroid dehydrogenase-2 deficiency and progesterone resistance in endometriosis. Semin Reprod Med 2010;28:44–50.
   PubMedGoogle Scholar
• Zeitoun K, Takayama K, Sasano H, et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998;83:4474–80.
   PubMed Web of Science ®Google Scholar
• Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600–6.
   PubMed Web of Science ®Google Scholar
• Abulafia O, Sherer DM. Angiogenesis of the endometrium. Obstet Gynecol 1999;94:148–53.
   PubMed Web of Science ®Google Scholar
• Bergquist A, Ljungberg O, Skoog L. Immunohistochemical analysis of oestrogen and progesterone receptors in endometriotic tissue and endometrium. Hum Reprod 1993;8:1915–22.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Gillespie DG, Zacharia LC, et al. Methoxyestradiols mediate the antimitogenic effects of locally applied estradiol on cardiac fibroblast growth. Hypertension 2002;39:412–17.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Jackson EK, Gillespie DG, et al. Cytochromes 1A1/1B1- and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J Clin Endocrinol Metab 2005;90:247–55.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Gillespie DG, Keller PJ, et al. Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension 2002;39:418–24.
   PubMed Web of Science ®Google Scholar
• Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1–37.
   PubMed Web of Science ®Google Scholar
• Tsutsui T, Tamura Y, Yagi E, Barrett JC. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int J Cancer 2000;86:8–14.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Gillespie DG, Zacharia LC, et al. CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension 2003;41:807–13.
   PubMed Web of Science ®Google Scholar
• Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269–77.
   PubMed Web of Science ®Google Scholar
• Sattler M, Quinnan LR, Pride YB, et al. 2-Methoxyestradiol alters cell motility, migration, and adhesion. Blood 2003;102:289–96.
   PubMed Web of Science ®Google Scholar
• Li JJ, Li SA, Oberley TD, Parsons JA. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation. Cancer Res 1995;55:4347–51.
   PubMed Web of Science ®Google Scholar
• Seeger H, Hadji P, Mueck AO. Endogenous estradiol metabolites stimulate the in vitro proliferation of human osteoblastic cells. Int J Clin Pharmacol Ther 2003;41:148–52.
   PubMed Web of Science ®Google Scholar
• Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237–9.
   PubMed Web of Science ®Google Scholar
• Matei D, Schilder J, Sutton G, et al. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 2009;115:90–6.
   PubMed Web of Science ®Google Scholar
• James J, Murry DJ, Treston AM, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25:41–8.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Chan JA, Meyerhardt JA, et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol 2011;68:293–300.
   PubMed Web of Science ®Google Scholar
• Machado-Linde F, Pelegrin P, Sanchez-Ferrer ML, et al. 2-Methoxyestradiol in the pathophysiology of endometriosis: focus on angiogenesis and therapeutic potential. Reprod Sci 2012;19:1018–29.
   PubMed Web of Science ®Google Scholar
• Becker CM, Rohwer N, Funakoshi T, et al. 2-Methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008;172:534–44.
   PubMed Web of Science ®Google Scholar
• Zeitvogel A, Baumann R, Starzinski-Powitz A. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 2001;159:1839–52.
   PubMed Web of Science ®Google Scholar
• Liu S, Meng X, Chen H, et al. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget 2014;5:9049–64.
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. J Steroid Biochem Mol Biol 2004;88:265–75.
   PubMed Web of Science ®Google Scholar
• Zacharia LC, Piche CA, Fielding RM, et al. 2-Hydroxyestradiol is a prodrug of 2-methoxyestradiol. J Pharmacol Exp Ther 2004;309:1093–7.
   PubMed Web of Science ®Google Scholar
• Zacharia LC, Gogos JA, Karayiorgou M, et al. Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol-O-methyltransferase-knockout mice. Circulation 2003;108:2974–8.
   PubMed Web of Science ®Google Scholar
• Zacharia LC, Jackson EK, Gillespie DG, Dubey RK. Catecholamines block 2-hydroxyestradiol-induced antimitogenesis in mesangial cells. Hypertension 2002;39:854–9.
   PubMed Web of Science ®Google Scholar
• Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165–72.
   PubMed Web of Science ®Google Scholar
• Dubey RK, Gillespie DG, Zacharia LC, et al. Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun 2000;278:27–33.
   PubMed Web of Science ®Google Scholar
• Verenich S, Gerk PM. Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm 2010;7:2030–9.
   PubMed Web of Science ®Google Scholar
• Gogusev J, Bouquet de Joliniere J, Telvi L, et al. Cellular and genetic constitution of human endometriosis tissues. J Soc Gynecol Investig 2000;7:79–87.
   PubMedGoogle Scholar